Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft

John E. Wagner, Claudio G. Brunstein, Anthony E. Boitano, Todd E. Defor, David McKenna, Darin Sumstad, Bruce R. Blazar, Jakub Tolar, Chap Le, Julie Jones, Michael P. Cooke, Conrad C. Bleul

Research output: Contribution to journalArticle

146 Scopus citations

Abstract

Clinical application of umbilical cord blood (UCB) as a source of hematopoietic stem cells for transplantation is limited by low CD34+ cell dose, increased risk of graft failure, and slow hematopoietic recovery. While the cell dose limitation is partially mitigated by using two UCB units, larger-dosed single units would be preferable. We have evaluated the feasibility and safety of StemRegenin-1 (SR-1), an aryl hydrocarbon receptor antagonist that expands CD34+ cells, by placing one of the two units in expansion culture. SR-1 produced a 330-fold increase in CD34+ cells and led to engraftment in 17/17 patients at a median of 15 days for neutrophils and 49 days for platelets, significantly faster than in patients treated with unmanipulated UCB. Taken together, the marked expansion, absence of graft failure, and enhanced hematopoietic recovery support testing of SR-1 expansion as a stand-alone graft and suggest it may ameliorate a limitation of UCB transplant.

Original languageEnglish (US)
Pages (from-to)144-155
Number of pages12
JournalCell Stem Cell
Volume18
Issue number1
DOIs
StatePublished - Jan 7 2016

Fingerprint Dive into the research topics of 'Phase I/II Trial of StemRegenin-1 Expanded Umbilical Cord Blood Hematopoietic Stem Cells Supports Testing as a Stand-Alone Graft'. Together they form a unique fingerprint.

  • Cite this